^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Lunsumio (mosunetuzumab-axgb)

i
Other names: RG7828, BTCT4465A, RG 7828, BTCT 4465A, RO7030816, CD20-TBD, BTCT-4465A, RG-7828, RO 7030816, RO-7030816
Company:
Biogen, Roche
Drug class:
CD20 inhibitor, CD3 agonist
Related drugs:
13d
NCI-2021-12489: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=42, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Mar 2025 | Trial primary completion date: Dec 2025 --> Mar 2025
Enrollment closed • Trial completion date • Trial primary completion date
|
Gazyva (obinutuzumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
1m
The landscape of T-cell engagers for the treatment of follicular lymphoma. (PubMed, Oncoimmunology)
CD3 × CD20 BsAbs have shown the most promise in clinical development for B-NHL patients, with structural variations affecting their target affinity and potency. This review summarizes the current clinical trials of BsAbs for relapsed/refractory FL, highlighting the approval of some agents, their role in first-line treatment or combination therapies, their toxicity profiles, and the future of this therapeutic approach compared to other immune cell therapies.
Review • Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
Epkinly (epcoritamab-bysp) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • Ordspono (odronextamab)
1m
Trial termination
|
Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Lunsumio (mosunetuzumab-axgb)
1m
Recent advances in the treatment of DLBCL (PubMed, Rinsho Ketsueki)
Treatment with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone has become the standard of care for newly diagnosed CD20-positive DLBCL with an International Prognostic Index score of 2 to 5, based on its reported efficacy for this indication. In addition, the development of immunotherapy such as anti-CD19-chimeric antigen receptor (CAR)-T therapy and bispecific antibodies such as epcoritamab, mosunetuzumab, and glofitamab has led to a paradigm shift in treatment of relapsed/refractory DLBCL. This review summarizes the evolution of treatment development for DLBCL, as well as the results of the current clinical standard of care and new therapies that are expected to become the standard of care.
Review • Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm)
1m
CO43805: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=121, Recruiting, Hoffmann-La Roche | Trial completion date: Mar 2029 --> Jul 2028 | Trial primary completion date: Mar 2027 --> Jul 2026
Trial completion date • Trial primary completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 expression
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • iberdomide (CC-220) • Columvi (glofitamab-gxbm) • golcadomide (CC-99282)
2ms
Trial completion date • Trial primary completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 expression
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • iberdomide (CC-220) • Columvi (glofitamab-gxbm) • golcadomide (CC-99282)
2ms
SUNMO: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P3, N=222, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Nov 2027 --> Feb 2027 | Trial primary completion date: May 2025 --> Feb 2025
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
gemcitabine • Rituxan (rituximab) • oxaliplatin • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
2ms
Enrollment closed
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
CD20 expression
|
Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)
2ms
New P2 trial
|
clonoSEQ
|
doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
2ms
Enrollment open
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
CD20 expression
|
lenalidomide • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)
3ms
New P2 trial
|
Lunsumio (mosunetuzumab-axgb)
3ms
New P2 trial
|
Brukinsa (zanubrutinib) • Lunsumio (mosunetuzumab-axgb)
3ms
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma (clinicaltrials.gov)
P2, N=41, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2027 --> Mar 2028
Enrollment open • Trial completion date • Trial primary completion date
|
Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
4ms
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma (clinicaltrials.gov)
P2, N=20, Recruiting, University of Washington | Not yet recruiting --> Recruiting
Enrollment open
|
Lunsumio (mosunetuzumab-axgb)
4ms
Enrollment open • Combination therapy
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Lunsumio (mosunetuzumab-axgb)
4ms
New P2 trial
|
Brukinsa (zanubrutinib) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)
5ms
New P2 trial
|
Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
5ms
Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States. (PubMed, Front Immunol)
Scenarios one and two resulted in ICERs of $105,353 and $102,695, respectively. This study finds that axi-cel is cost-effective compared to mosun at the commonly cited $150,000/QALY US willingness-to-pay threshold, with robust results across a range of sensitivity analyses accounting for parameter uncertainty.
Clinical • Journal • HEOR • Cost-effectiveness • Cost effectiveness
|
CD20 (Membrane Spanning 4-Domains A1)
|
Yescarta (axicabtagene ciloleucel) • Lunsumio (mosunetuzumab-axgb)
5ms
New P2 trial
|
Lunsumio (mosunetuzumab-axgb)
5ms
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
P1, N=30, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
Trial completion date • Trial primary completion date
|
IFNG (Interferon, gamma) • CD79B (CD79b Molecule) • CD4 (CD4 Molecule)
|
lenalidomide • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
6ms
Trial primary completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1)
|
Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
6ms
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma. (PubMed, Clin Transl Sci)
Prior to Mosun treatment, ~50% of patients had residual levels of anti-CD20 drugs (e.g., rituximab or obinutuzumab) from prior treatment. The 60 mg loading doses increased Mosun CD20 RO% in Cycle 1, providing efficacious exposures in the presence of the competing anti-CD20 drugs. PopPK model simulations, investigating Mosun dose delays, informed treatment resumption protocols to ensure CRS mitigation.
PK/PD data • Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
Rituxan (rituximab) • Gazyva (obinutuzumab) • Lunsumio (mosunetuzumab-axgb)
6ms
Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
lenalidomide • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)
6ms
Trial initiation date
|
IFNG (Interferon, gamma) • CD79B (CD79b Molecule) • CD4 (CD4 Molecule)
|
lenalidomide • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
6ms
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma (clinicaltrials.gov)
P1, N=15, Recruiting, Washington University School of Medicine | Trial completion date: Jun 2027 --> Jun 2029
Trial completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
Lunsumio (mosunetuzumab-axgb)
6ms
MorningLyte: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 (clinicaltrials.gov)
P3, N=790, Recruiting, The Lymphoma Academic Research Organisation | Not yet recruiting --> Recruiting
Enrollment open
|
Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • prednisone • bendamustine • Lunsumio (mosunetuzumab-axgb)
6ms
Enrollment closed
|
Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)
7ms
Disrupting B and T cell Collaboration in Autoimmune Disease: T cell engagers versus CAR T cell therapy? (PubMed, Clin Exp Immunol)
Historically, B and T cell (B-T cell) co-interaction was targeted through different pathways such as alemtuzumab, abatacept, and dapirolizumab with variable impact on B cell depletion (BCD), whereas the majority of patients with AID including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and organ transplantation benefit from targeted BCD with anti-CD20 monoclonal antibodies such as rituximab, ocrelizumab or ofatumumab...In the treatment of cancer, chimeric antigen receptor (CAR) T cell therapy and T cell engagers (TCE) that recruit T cells to induce B cell cytotoxicity have delivered promising results for anti-CD19 CAR T cell therapies, the CD19 TCE blinatumomab and CD20 TCE such as mosunetuzumab, glofitamab or epcoritamab. Limited evidence suggests that anti-CD19 CAR T cell therapy may be effective in managing refractory AID whereas we await evaluation of TCE for use in non-oncological indications. Therefore, here, we discuss the potential mechanistic advantages of novel therapies that rely on T cells as effector cells to disrupt B-T cell collaboration toward overcoming rituximab-resistant AID.
Journal • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD27 (CD27 Molecule)
|
CD19 expression
|
Rituxan (rituximab) • Blincyto (blinatumomab) • Epkinly (epcoritamab-bysp) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • Ocrevus (ocrelizumab)
7ms
Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
CD20 expression
|
lenalidomide • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)
7ms
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=396, Recruiting, SWOG Cancer Research Network | Trial primary completion date: Dec 2024 --> Dec 2025
Trial primary completion date • CAR T-Cell Therapy
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
8ms
New P3 trial
|
Rituxan Hycela (rituximab/hyaluronidase) • Lunsumio (mosunetuzumab-axgb) • Mabtas (rituximab biosimilar)
8ms
NCI-2021-12489: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=42, Recruiting, University of Washington | Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
Gazyva (obinutuzumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
8ms
Trial primary completion date • Combination therapy
|
Rituxan (rituximab) • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
9ms
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=8, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | N=118 --> 8 | Trial completion date: Dec 2023 --> Jul 2023 | Trial primary completion date: Dec 2023 --> Jul 2023
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Lunsumio (mosunetuzumab-axgb)
9ms
New P3 trial
|
Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • prednisone • bendamustine • Lunsumio (mosunetuzumab-axgb)
9ms
Trial initiation date
|
CD20 (Membrane Spanning 4-Domains A1) • PD-1 (Programmed cell death 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
CD20 expression
|
Rituxan Hycela (rituximab/hyaluronidase) • Lunsumio (mosunetuzumab-axgb) • Mabtas (rituximab biosimilar)
9ms
GO29781: A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1/2, N=836, Active, not recruiting, Genentech, Inc. | Trial completion date: Nov 2023 --> Nov 2025 | Trial primary completion date: Nov 2023 --> Nov 2025
Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
Tecentriq (atezolizumab) • Lunsumio (mosunetuzumab-axgb)
9ms
New P1/2 trial
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Lunsumio (mosunetuzumab-axgb)
11ms
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
P1, N=30, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: May 2025 --> Dec 2025 | Initiation date: Dec 2023 --> Sep 2024 | Trial primary completion date: May 2025 --> Dec 2025
Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
|
IFNG (Interferon, gamma) • CD79B (CD79b Molecule) • CD4 (CD4 Molecule)
|
CD79B expression
|
lenalidomide • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
11ms
Enrollment open • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1)
|
Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
11ms
Phase classification
|
Gazyva (obinutuzumab) • Zynlonta (loncastuximab tesirine-lpyl) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm)
11ms
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov)
P1, N=137, Recruiting, Hoffmann-La Roche | N=56 --> 137 | Trial completion date: Jul 2027 --> Oct 2029 | Trial primary completion date: Feb 2026 --> May 2027
Enrollment change • Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)